生存模型中多个随机变化点的贝叶斯分析在临床试验中的应用。

IF 1.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Journal of Biopharmaceutical Statistics Pub Date : 2024-09-22 DOI:10.1080/10543406.2024.2395542
Jianbo Xu
{"title":"生存模型中多个随机变化点的贝叶斯分析在临床试验中的应用。","authors":"Jianbo Xu","doi":"10.1080/10543406.2024.2395542","DOIUrl":null,"url":null,"abstract":"<p><p>Single and multiple random change points (RCPs) in survival analysis have arisen naturally in oncology trials, where the time to hazard rate change differs from one subject to another. Recently, Xu formulated and discovered important properties of these survival models using a frequentist approach, allowing us to estimate the hazard rates, rate parameters of the exponential distributions for the RCPs, expected survival and hazard functions. However, these methods did not provide an estimation of the uncertainty or the confidence intervals for the parameters and their differences or ratios. Therefore, statistical inferences were not able to be drawn on the parameters and their comparisons. To solve this issue, this article implements a Gibbs sampler method to estimate the above parameters and the differences or ratios alongside the 100(1 <math><mo>-</mo></math> <math><mi>α</mi></math>)% highest posterior density (HPD) intervals calculated from Chen-Shao's algorithm. The estimated rate parameters from the methods in Xu serve as empirical values in the Gibbs sampler method. Thus, formal statistical inferences can now be readily drawn. Simulation studies demonstrate that the proposed methods yield robust estimates, with the samples from the marginal posterior distributions converging rapidly and exhibiting favorable behavior. The 95% HPD intervals also demonstrate excellent coverage probabilities. This proposed method has a multitude of applications in clinical trials such as efficient clinical trial design and sample size adjustment based on the estimated parameter values at interim analyses.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-18"},"PeriodicalIF":1.2000,"publicationDate":"2024-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bayesian analyses of multiple random change points in survival models with applications to clinical trials.\",\"authors\":\"Jianbo Xu\",\"doi\":\"10.1080/10543406.2024.2395542\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Single and multiple random change points (RCPs) in survival analysis have arisen naturally in oncology trials, where the time to hazard rate change differs from one subject to another. Recently, Xu formulated and discovered important properties of these survival models using a frequentist approach, allowing us to estimate the hazard rates, rate parameters of the exponential distributions for the RCPs, expected survival and hazard functions. However, these methods did not provide an estimation of the uncertainty or the confidence intervals for the parameters and their differences or ratios. Therefore, statistical inferences were not able to be drawn on the parameters and their comparisons. To solve this issue, this article implements a Gibbs sampler method to estimate the above parameters and the differences or ratios alongside the 100(1 <math><mo>-</mo></math> <math><mi>α</mi></math>)% highest posterior density (HPD) intervals calculated from Chen-Shao's algorithm. The estimated rate parameters from the methods in Xu serve as empirical values in the Gibbs sampler method. Thus, formal statistical inferences can now be readily drawn. Simulation studies demonstrate that the proposed methods yield robust estimates, with the samples from the marginal posterior distributions converging rapidly and exhibiting favorable behavior. The 95% HPD intervals also demonstrate excellent coverage probabilities. This proposed method has a multitude of applications in clinical trials such as efficient clinical trial design and sample size adjustment based on the estimated parameter values at interim analyses.</p>\",\"PeriodicalId\":54870,\"journal\":{\"name\":\"Journal of Biopharmaceutical Statistics\",\"volume\":\" \",\"pages\":\"1-18\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Biopharmaceutical Statistics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10543406.2024.2395542\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2024.2395542","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

生存分析中的单个和多个随机变化点(RCPs)在肿瘤试验中自然出现,不同受试者的危险率变化时间不同。最近,Xu 使用频繁主义方法制定并发现了这些生存模型的重要属性,使我们能够估计危险率、随机变化点指数分布的速率参数、预期生存期和危险函数。然而,这些方法并不能估算参数及其差异或比率的不确定性或置信区间。因此,无法对参数及其比较进行统计推断。为了解决这个问题,本文采用吉布斯采样器方法来估计上述参数及其差值或比值,同时利用陈绍算法计算出的 100(1 - α)% 最高后验密度(HPD)区间。在吉布斯采样器方法中,Xu 方法估算出的速率参数可作为经验值。因此,现在可以很容易地得出正式的统计推论。模拟研究表明,所提出的方法能产生稳健的估计值,边际后验分布的样本能迅速收敛并表现出良好的行为。95% HPD 区间也显示出极佳的覆盖概率。所提出的方法在临床试验中有着广泛的应用,如根据中期分析的估计参数值进行高效的临床试验设计和样本量调整。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Bayesian analyses of multiple random change points in survival models with applications to clinical trials.

Single and multiple random change points (RCPs) in survival analysis have arisen naturally in oncology trials, where the time to hazard rate change differs from one subject to another. Recently, Xu formulated and discovered important properties of these survival models using a frequentist approach, allowing us to estimate the hazard rates, rate parameters of the exponential distributions for the RCPs, expected survival and hazard functions. However, these methods did not provide an estimation of the uncertainty or the confidence intervals for the parameters and their differences or ratios. Therefore, statistical inferences were not able to be drawn on the parameters and their comparisons. To solve this issue, this article implements a Gibbs sampler method to estimate the above parameters and the differences or ratios alongside the 100(1 - α)% highest posterior density (HPD) intervals calculated from Chen-Shao's algorithm. The estimated rate parameters from the methods in Xu serve as empirical values in the Gibbs sampler method. Thus, formal statistical inferences can now be readily drawn. Simulation studies demonstrate that the proposed methods yield robust estimates, with the samples from the marginal posterior distributions converging rapidly and exhibiting favorable behavior. The 95% HPD intervals also demonstrate excellent coverage probabilities. This proposed method has a multitude of applications in clinical trials such as efficient clinical trial design and sample size adjustment based on the estimated parameter values at interim analyses.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.50
自引率
18.20%
发文量
71
审稿时长
6-12 weeks
期刊介绍: The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers: Drug, device, and biological research and development; Drug screening and drug design; Assessment of pharmacological activity; Pharmaceutical formulation and scale-up; Preclinical safety assessment; Bioavailability, bioequivalence, and pharmacokinetics; Phase, I, II, and III clinical development including complex innovative designs; Premarket approval assessment of clinical safety; Postmarketing surveillance; Big data and artificial intelligence and applications.
期刊最新文献
Sequential monitoring of cancer immunotherapy trial with random delayed treatment effect. Directed Acyclic Graph Assisted Method For Estimating Average Treatment Effect. Bayesian phase II adaptive randomization by jointly modeling efficacy and toxicity as time-to-event outcomes. Interval estimation of relative risks for combined unilateral and bilateral correlated data. Sample size estimation for recurrent event data using multifrailty and multilevel survival models.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1